Seuraa
Toomas Asser
Toomas Asser
University of Tartu
Vahvistettu sähköpostiosoite verkkotunnuksessa kliinikum.ee
Nimike
Viittaukset
Viittaukset
Vuosi
Seizure disorders in patients with brain tumors
A Liigant, S Haldre, A Õun, Ü Linnamägi, A Saar, T Asser, AE Kaasik
European neurology 45 (1), 46-51, 2001
1492001
Cerebral hemodynamic impairment after aneurysmal subarachnoid hemorrhage as evaluated using transcranial Doppler ultrasonography: relationship to delayed cerebral ischemia and …
T Rätsep, T Asser
Journal of neurosurgery 95 (3), 393-401, 2001
1192001
Tissue plasminogen activator and neuroserpin are widely expressed in the human central nervous system
T Teesalu, A Kulla, A Simisker, V Sirén, DA Lawrence, T Asser, A Vaheri
Thrombosis and haemostasis 92 (08), 358-368, 2004
1152004
Irreversible motor impairment in young addicts–ephedrone, manganism or both?
K Sikk, P Taba, S Haldre, J Bergquist, D Nyholm, G Zjablov, T Asser, ...
Acta Neurologica Scandinavica 115 (6), 385-389, 2007
892007
Peptide-guided nanoparticles for glioblastoma targeting
P Säälik, P Lingasamy, K Toome, I Mastandrea, L Rousso-Noori, A Tobi, ...
Journal of Controlled Release 308, 109-118, 2019
842019
High incidence of traumatic spinal cord injury in Estonia
L Sabre, G Pedai, T Rekand, T Asser, Ü Linnamägi, J Kõrv
Spinal cord 50 (10), 755-759, 2012
752012
Epidemiology of primary central nervous system tumors in Estonia
A Liigant, T Asser, A Kulla, AE Kaasik
Neuroepidemiology 19 (6), 300-311, 2000
642000
Relationship between neovascularization and degenerative changes in herniated lumbar intervertebral discs
T Rätsep, A Minajeva, T Asser
European Spine Journal 22, 2474-2480, 2013
632013
Tissue plasminogen activator as a key effector in neurobiology and neuropathology
T Teesalu, A Kulla, T Asser, M Koskiniemi, A Vaheri
Biochemical Society Transactions 30 (2), 183-189, 2002
632002
Tumor-penetrating peptide for systemic targeting of Tenascin-C
P Lingasamy, A Tobi, K Kurm, S Kopanchuk, A Sudakov, M Salumäe, ...
Scientific Reports 10 (1), 5809, 2020
592020
The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury
H Shakur, P Andrews, T Asser, L Balica, C Boeriu, JDC Quintero, ...
Trials 10, 1-10, 2009
592009
Bi-specific tenascin-C and fibronectin targeted peptide for solid tumor delivery
P Lingasamy, A Tobi, M Haugas, H Hunt, P Paiste, T Asser, T Rätsep, ...
Biomaterials 219, 119373, 2019
562019
Changes in viscoelastic properties of skeletal muscles induced by subthalamic stimulation in patients with Parkinson's disease
T Rätsep, T Asser
Clinical biomechanics 26 (2), 213-217, 2011
562011
A snapshot of European neurosurgery December 2019 vs. March 2020: just before and during the Covid-19 pandemic
T Mathiesen, M Arraez, T Asser, N Balak, S Barazi, C Bernucci, C Bolger, ...
Acta neurochirurgica 162, 2221-2233, 2020
552020
Prevalence of Parkinson's disease in Estonia
P Taba, T Asser
Acta neurologica scandinavica 106 (5), 276-281, 2002
522002
Mortality and causes of death after traumatic spinal cord injury in Estonia
L Sabre, T Rekand, T Asser, J Kõrv
The Journal of Spinal Cord Medicine 36 (6), 687-694, 2013
512013
Emotional health and quality of life after aneurysmal subarachnoid hemorrhage
A Vetkas, T Lepik, T Eilat, T Rätsep, T Asser
Acta neurochirurgica 155, 1107-1114, 2013
492013
Possible interpretation of subjective complaints in patients with spontaneous subarachnoid haemorrhage.
A Toomela, A Pulver, T Tomberg, A Orasson, A Tikk, T Asser
Journal of Rehabilitation Medicine 36 (2), 63-69, 2004
412004
Impact of PARP-1 and DNA-PK expression on survival in patients with glioblastoma multiforme
M Kase, M Vardja, A Lipping, T Asser, J Jaal
Radiotherapy and Oncology 101 (1), 127-131, 2011
382011
Traumatic spinal cord injury in two E uropean countries: why the differences?
L Sabre, EM Hagen, T Rekand, T Asser, J Kõrv
European journal of neurology 20 (2), 293-299, 2013
362013
Järjestelmä ei voi suorittaa toimenpidettä nyt. Yritä myöhemmin uudelleen.
Artikkelit 1–20